Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2026,
Oculis Holding AG receivedkr3,525.52 Mil more from issuing new shares than it paid to buy back shares.
It spentkr16.07 Mil paying down its debt.
It paidkr0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedkr0.00 Mil from paying cash dividends to shareholders.
It receivedkr209.23 Mil on other financial activities.
In all, Oculis Holding AGearnedkr3,718.68 Mil on financial activities for the
three
months ended in Mar. 2026.
Oculis Holding AG (OISE:OCS) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Oculis Holding AG's issuance of stock for the
three
months ended in Mar. 2026 was kr3,525.52 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Oculis Holding AG's repurchase of stock for the
three
months ended in Mar. 2026 was kr0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Oculis Holding AG's net issuance of debt for the
three
months ended in Mar. 2026 was kr-16.07 Mil.
Oculis Holding AG spentkr16.07 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Oculis Holding AG's net issuance of preferred for the
three
months ended in Mar. 2026 was kr0.00 Mil.
Oculis Holding AG paidkr0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Oculis Holding AG's cash flow for dividends for the
three
months ended in Mar. 2026 was kr0.00 Mil.
Oculis Holding AG receivedkr0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Oculis Holding AG's other financing for the
three
months ended in Mar. 2026 was kr209.23 Mil.
Oculis Holding AG receivedkr209.23 Mil on other financial activities.
Oculis Holding AG Cash Flow from Financing Related Terms
Oculis Holding AG Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Oculis Holding AG's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oculis Holding AG Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Oculis Holding AG's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr16,649.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of kr16,649.28 Mil mean?
Oculis Holding AG (OISE:OCS) has a Cash Flow from Financing of kr16,649.28 Mil as of Mar. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Oculis Holding AG and its competitors.
Is Oculis Holding AG's Cash Flow from Financing too high?
Oculis Holding AG's current Cash Flow from Financing is kr16,649.28 Mil. Overall, Oculis Holding AG has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Oculis Holding AG's Cash Flow from Financing compare to RIGL and GYRE?
Oculis Holding AG's Cash Flow from Financing of kr16,649.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Biotechnology company?
A good Cash Flow from Financing depends on the Biotechnology industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Oculis Holding AG and its competitors. Oculis Holding AG's current Cash Flow from Financing is kr16,649.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oculis Holding AG stock overvalued right now?
Oculis Holding AG (OISE:OCS) has a current Cash Flow from Financing of kr16,649.28 Mil. The current Cash Flow from Financing is kr16,649.28 Mil. Oculis Holding AG's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Oculis Holding AG (OISE:OCS), the current Cash Flow from Financing is kr16,649.28 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
26GF Score
Get the complete analysis for OISE:OCS
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OISE:OCS has been successfully added to your 
